Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication ‐ a prospective study for up to 10 years
Summary Background Atrophic gastritis and intestinal metaplasia are premalignant conditions for gastric cancer. Their reversibility by Helicobacter pylori eradication remains controversial. Aim To evaluate the reversibility of atrophic gastritis and intestinal metaplasia by H. pylori eradication wit...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2018-02, Vol.47 (3), p.380-390 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 390 |
|---|---|
| container_issue | 3 |
| container_start_page | 380 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 47 |
| creator | Hwang, Y.‐J. Kim, N. Lee, H. S. Lee, J. B. Choi, Y. J. Yoon, H. Shin, C. M. Park, Y. S. Lee, D. H. |
| description | Summary
Background
Atrophic gastritis and intestinal metaplasia are premalignant conditions for gastric cancer. Their reversibility by Helicobacter pylori eradication remains controversial.
Aim
To evaluate the reversibility of atrophic gastritis and intestinal metaplasia by H. pylori eradication with long‐term follow‐up.
Methods
598 subjects were prospectively enrolled and followed for up to 10 years. They were categorised as H. pylori‐negative (n = 65), H. pylori non‐eradicated (n = 91), and H. pylori‐eradicated (n = 442). Histological assessment was performed for antrum and corpus by Sydney classification.
Results
Histological follow‐up was performed regularly at 1, 2, 3‐4 and ≥5 years, with mean follow‐up of 1.07 ± 0.21, 2.29 ± 0.83, 3.93 ± 1.02, and 6.45 ± 1.28 years, respectively. Atrophic gastritis in antrum and corpus gradually and significantly (both P < .05 for all timepoints) improved only in the H. pylori‐eradicated group compared to that at baseline. Significant difference in atrophic gastritis between H. pylori‐eradicated and H. pylori‐negative groups disappeared from 1‐year follow‐up. Similarly, intestinal metaplasia in antrum and corpus improved significantly (both P < .05 for all timepoints) only in the H. pylori‐eradicated group in comparison with that at baseline. Significant difference in intestinal metaplasia between H. pylori‐eradicated and H. pylori‐negative groups disappeared from ≥5 years of follow‐up in the antrum and from 3 years of follow‐up in the corpus.
Conclusion
H. pylori eradication may be a preventative strategy for intestinal‐type gastric cancer by regression of atrophic gastritis and intestinal metaplasia.
Linked ContentThis article is linked to Genta and Kim and Hwang papers. To view these articles visit https://doi.org/10.1111/apt.14491 and https://doi.org/10.1111/apt.14524. |
| doi_str_mv | 10.1111/apt.14424 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1971652604</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1985684040</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4544-3716f201fbad48954b38171a6c874e25e6bd8d04e2c23ecd528c2d705513d5673</originalsourceid><addsrcrecordid>eNp1kctu1TAQhi1ERQ-FBS-ALLEpi7S-J1lWFaVIlYpQWUcTewKucuJgO0XZ9QkqnpEnwYdTWCAxm5mRPv1z-Ql5xdkJL3EKcz7hSgn1hGy4NLoSTJqnZMOEaSvRcHlInqd0yxgzNRPPyKFoeSsFrzfk4RPeYUy-96PPKw0DhRzD_NVb-gVSjj77RGFy1E8ZU_YTjHSLGeYRkgcKQ8ZIL3H0NvRgd828jiF6ihGct5B9mOjP-x8U6BxDmtFmf4c05cWtdAiRLjPNgXJGV4SYXpCDAcaELx_zEfl88e7m_LK6un7_4fzsqrJKK1XJmptBMD704FTTatXLhtccjG1qhUKj6V3jWCmtkGidFo0VrmZac-m0qeUROd7rlqW-LeWwbuuTxXGECcOSOt6WCVoYpgr65h_0Niyx_GFHNdo0iilWqLd7ypYrU8Shm6PfQlw7zrqdSV0xqfttUmFfPyou_RbdX_KPKwU43QPf_Yjr_5W6s483e8lffDyddA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1985684040</pqid></control><display><type>article</type><title>Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication ‐ a prospective study for up to 10 years</title><source>MEDLINE</source><source>Wiley Online Library Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>Hwang, Y.‐J. ; Kim, N. ; Lee, H. S. ; Lee, J. B. ; Choi, Y. J. ; Yoon, H. ; Shin, C. M. ; Park, Y. S. ; Lee, D. H.</creator><creatorcontrib>Hwang, Y.‐J. ; Kim, N. ; Lee, H. S. ; Lee, J. B. ; Choi, Y. J. ; Yoon, H. ; Shin, C. M. ; Park, Y. S. ; Lee, D. H.</creatorcontrib><description>Summary
Background
Atrophic gastritis and intestinal metaplasia are premalignant conditions for gastric cancer. Their reversibility by Helicobacter pylori eradication remains controversial.
Aim
To evaluate the reversibility of atrophic gastritis and intestinal metaplasia by H. pylori eradication with long‐term follow‐up.
Methods
598 subjects were prospectively enrolled and followed for up to 10 years. They were categorised as H. pylori‐negative (n = 65), H. pylori non‐eradicated (n = 91), and H. pylori‐eradicated (n = 442). Histological assessment was performed for antrum and corpus by Sydney classification.
Results
Histological follow‐up was performed regularly at 1, 2, 3‐4 and ≥5 years, with mean follow‐up of 1.07 ± 0.21, 2.29 ± 0.83, 3.93 ± 1.02, and 6.45 ± 1.28 years, respectively. Atrophic gastritis in antrum and corpus gradually and significantly (both P < .05 for all timepoints) improved only in the H. pylori‐eradicated group compared to that at baseline. Significant difference in atrophic gastritis between H. pylori‐eradicated and H. pylori‐negative groups disappeared from 1‐year follow‐up. Similarly, intestinal metaplasia in antrum and corpus improved significantly (both P < .05 for all timepoints) only in the H. pylori‐eradicated group in comparison with that at baseline. Significant difference in intestinal metaplasia between H. pylori‐eradicated and H. pylori‐negative groups disappeared from ≥5 years of follow‐up in the antrum and from 3 years of follow‐up in the corpus.
Conclusion
H. pylori eradication may be a preventative strategy for intestinal‐type gastric cancer by regression of atrophic gastritis and intestinal metaplasia.
Linked ContentThis article is linked to Genta and Kim and Hwang papers. To view these articles visit https://doi.org/10.1111/apt.14491 and https://doi.org/10.1111/apt.14524.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.14424</identifier><identifier>PMID: 29193217</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Gastric cancer ; Gastritis ; Gastritis, Atrophic - microbiology ; Gastritis, Atrophic - pathology ; Gastritis, Atrophic - rehabilitation ; Helicobacter Infections - complications ; Helicobacter Infections - pathology ; Helicobacter Infections - therapy ; Helicobacter pylori ; Helicobacter pylori - physiology ; Humans ; Intestine ; Intestines - microbiology ; Intestines - pathology ; Male ; Metaplasia ; Metaplasia - microbiology ; Metaplasia - rehabilitation ; Middle Aged ; Mucous membrane ; Pathogens ; Precancerous Conditions - microbiology ; Precancerous Conditions - rehabilitation ; Recovery of Function - physiology ; Risk Factors ; Young Adult</subject><ispartof>Alimentary pharmacology & therapeutics, 2018-02, Vol.47 (3), p.380-390</ispartof><rights>2017 John Wiley & Sons Ltd</rights><rights>2017 John Wiley & Sons Ltd.</rights><rights>Copyright © 2018 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4544-3716f201fbad48954b38171a6c874e25e6bd8d04e2c23ecd528c2d705513d5673</citedby><cites>FETCH-LOGICAL-c4544-3716f201fbad48954b38171a6c874e25e6bd8d04e2c23ecd528c2d705513d5673</cites><orcidid>0000-0002-9397-0406</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.14424$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.14424$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29193217$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hwang, Y.‐J.</creatorcontrib><creatorcontrib>Kim, N.</creatorcontrib><creatorcontrib>Lee, H. S.</creatorcontrib><creatorcontrib>Lee, J. B.</creatorcontrib><creatorcontrib>Choi, Y. J.</creatorcontrib><creatorcontrib>Yoon, H.</creatorcontrib><creatorcontrib>Shin, C. M.</creatorcontrib><creatorcontrib>Park, Y. S.</creatorcontrib><creatorcontrib>Lee, D. H.</creatorcontrib><title>Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication ‐ a prospective study for up to 10 years</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background
Atrophic gastritis and intestinal metaplasia are premalignant conditions for gastric cancer. Their reversibility by Helicobacter pylori eradication remains controversial.
Aim
To evaluate the reversibility of atrophic gastritis and intestinal metaplasia by H. pylori eradication with long‐term follow‐up.
Methods
598 subjects were prospectively enrolled and followed for up to 10 years. They were categorised as H. pylori‐negative (n = 65), H. pylori non‐eradicated (n = 91), and H. pylori‐eradicated (n = 442). Histological assessment was performed for antrum and corpus by Sydney classification.
Results
Histological follow‐up was performed regularly at 1, 2, 3‐4 and ≥5 years, with mean follow‐up of 1.07 ± 0.21, 2.29 ± 0.83, 3.93 ± 1.02, and 6.45 ± 1.28 years, respectively. Atrophic gastritis in antrum and corpus gradually and significantly (both P < .05 for all timepoints) improved only in the H. pylori‐eradicated group compared to that at baseline. Significant difference in atrophic gastritis between H. pylori‐eradicated and H. pylori‐negative groups disappeared from 1‐year follow‐up. Similarly, intestinal metaplasia in antrum and corpus improved significantly (both P < .05 for all timepoints) only in the H. pylori‐eradicated group in comparison with that at baseline. Significant difference in intestinal metaplasia between H. pylori‐eradicated and H. pylori‐negative groups disappeared from ≥5 years of follow‐up in the antrum and from 3 years of follow‐up in the corpus.
Conclusion
H. pylori eradication may be a preventative strategy for intestinal‐type gastric cancer by regression of atrophic gastritis and intestinal metaplasia.
Linked ContentThis article is linked to Genta and Kim and Hwang papers. To view these articles visit https://doi.org/10.1111/apt.14491 and https://doi.org/10.1111/apt.14524.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastric cancer</subject><subject>Gastritis</subject><subject>Gastritis, Atrophic - microbiology</subject><subject>Gastritis, Atrophic - pathology</subject><subject>Gastritis, Atrophic - rehabilitation</subject><subject>Helicobacter Infections - complications</subject><subject>Helicobacter Infections - pathology</subject><subject>Helicobacter Infections - therapy</subject><subject>Helicobacter pylori</subject><subject>Helicobacter pylori - physiology</subject><subject>Humans</subject><subject>Intestine</subject><subject>Intestines - microbiology</subject><subject>Intestines - pathology</subject><subject>Male</subject><subject>Metaplasia</subject><subject>Metaplasia - microbiology</subject><subject>Metaplasia - rehabilitation</subject><subject>Middle Aged</subject><subject>Mucous membrane</subject><subject>Pathogens</subject><subject>Precancerous Conditions - microbiology</subject><subject>Precancerous Conditions - rehabilitation</subject><subject>Recovery of Function - physiology</subject><subject>Risk Factors</subject><subject>Young Adult</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctu1TAQhi1ERQ-FBS-ALLEpi7S-J1lWFaVIlYpQWUcTewKucuJgO0XZ9QkqnpEnwYdTWCAxm5mRPv1z-Ql5xdkJL3EKcz7hSgn1hGy4NLoSTJqnZMOEaSvRcHlInqd0yxgzNRPPyKFoeSsFrzfk4RPeYUy-96PPKw0DhRzD_NVb-gVSjj77RGFy1E8ZU_YTjHSLGeYRkgcKQ8ZIL3H0NvRgd828jiF6ihGct5B9mOjP-x8U6BxDmtFmf4c05cWtdAiRLjPNgXJGV4SYXpCDAcaELx_zEfl88e7m_LK6un7_4fzsqrJKK1XJmptBMD704FTTatXLhtccjG1qhUKj6V3jWCmtkGidFo0VrmZac-m0qeUROd7rlqW-LeWwbuuTxXGECcOSOt6WCVoYpgr65h_0Niyx_GFHNdo0iilWqLd7ypYrU8Shm6PfQlw7zrqdSV0xqfttUmFfPyou_RbdX_KPKwU43QPf_Yjr_5W6s483e8lffDyddA</recordid><startdate>201802</startdate><enddate>201802</enddate><creator>Hwang, Y.‐J.</creator><creator>Kim, N.</creator><creator>Lee, H. S.</creator><creator>Lee, J. B.</creator><creator>Choi, Y. J.</creator><creator>Yoon, H.</creator><creator>Shin, C. M.</creator><creator>Park, Y. S.</creator><creator>Lee, D. H.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9397-0406</orcidid></search><sort><creationdate>201802</creationdate><title>Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication ‐ a prospective study for up to 10 years</title><author>Hwang, Y.‐J. ; Kim, N. ; Lee, H. S. ; Lee, J. B. ; Choi, Y. J. ; Yoon, H. ; Shin, C. M. ; Park, Y. S. ; Lee, D. H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4544-3716f201fbad48954b38171a6c874e25e6bd8d04e2c23ecd528c2d705513d5673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastric cancer</topic><topic>Gastritis</topic><topic>Gastritis, Atrophic - microbiology</topic><topic>Gastritis, Atrophic - pathology</topic><topic>Gastritis, Atrophic - rehabilitation</topic><topic>Helicobacter Infections - complications</topic><topic>Helicobacter Infections - pathology</topic><topic>Helicobacter Infections - therapy</topic><topic>Helicobacter pylori</topic><topic>Helicobacter pylori - physiology</topic><topic>Humans</topic><topic>Intestine</topic><topic>Intestines - microbiology</topic><topic>Intestines - pathology</topic><topic>Male</topic><topic>Metaplasia</topic><topic>Metaplasia - microbiology</topic><topic>Metaplasia - rehabilitation</topic><topic>Middle Aged</topic><topic>Mucous membrane</topic><topic>Pathogens</topic><topic>Precancerous Conditions - microbiology</topic><topic>Precancerous Conditions - rehabilitation</topic><topic>Recovery of Function - physiology</topic><topic>Risk Factors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hwang, Y.‐J.</creatorcontrib><creatorcontrib>Kim, N.</creatorcontrib><creatorcontrib>Lee, H. S.</creatorcontrib><creatorcontrib>Lee, J. B.</creatorcontrib><creatorcontrib>Choi, Y. J.</creatorcontrib><creatorcontrib>Yoon, H.</creatorcontrib><creatorcontrib>Shin, C. M.</creatorcontrib><creatorcontrib>Park, Y. S.</creatorcontrib><creatorcontrib>Lee, D. H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hwang, Y.‐J.</au><au>Kim, N.</au><au>Lee, H. S.</au><au>Lee, J. B.</au><au>Choi, Y. J.</au><au>Yoon, H.</au><au>Shin, C. M.</au><au>Park, Y. S.</au><au>Lee, D. H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication ‐ a prospective study for up to 10 years</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2018-02</date><risdate>2018</risdate><volume>47</volume><issue>3</issue><spage>380</spage><epage>390</epage><pages>380-390</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background
Atrophic gastritis and intestinal metaplasia are premalignant conditions for gastric cancer. Their reversibility by Helicobacter pylori eradication remains controversial.
Aim
To evaluate the reversibility of atrophic gastritis and intestinal metaplasia by H. pylori eradication with long‐term follow‐up.
Methods
598 subjects were prospectively enrolled and followed for up to 10 years. They were categorised as H. pylori‐negative (n = 65), H. pylori non‐eradicated (n = 91), and H. pylori‐eradicated (n = 442). Histological assessment was performed for antrum and corpus by Sydney classification.
Results
Histological follow‐up was performed regularly at 1, 2, 3‐4 and ≥5 years, with mean follow‐up of 1.07 ± 0.21, 2.29 ± 0.83, 3.93 ± 1.02, and 6.45 ± 1.28 years, respectively. Atrophic gastritis in antrum and corpus gradually and significantly (both P < .05 for all timepoints) improved only in the H. pylori‐eradicated group compared to that at baseline. Significant difference in atrophic gastritis between H. pylori‐eradicated and H. pylori‐negative groups disappeared from 1‐year follow‐up. Similarly, intestinal metaplasia in antrum and corpus improved significantly (both P < .05 for all timepoints) only in the H. pylori‐eradicated group in comparison with that at baseline. Significant difference in intestinal metaplasia between H. pylori‐eradicated and H. pylori‐negative groups disappeared from ≥5 years of follow‐up in the antrum and from 3 years of follow‐up in the corpus.
Conclusion
H. pylori eradication may be a preventative strategy for intestinal‐type gastric cancer by regression of atrophic gastritis and intestinal metaplasia.
Linked ContentThis article is linked to Genta and Kim and Hwang papers. To view these articles visit https://doi.org/10.1111/apt.14491 and https://doi.org/10.1111/apt.14524.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29193217</pmid><doi>10.1111/apt.14424</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-9397-0406</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2018-02, Vol.47 (3), p.380-390 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1971652604 |
| source | MEDLINE; Wiley Online Library Free Content; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals |
| subjects | Adolescent Adult Aged Aged, 80 and over Female Follow-Up Studies Gastric cancer Gastritis Gastritis, Atrophic - microbiology Gastritis, Atrophic - pathology Gastritis, Atrophic - rehabilitation Helicobacter Infections - complications Helicobacter Infections - pathology Helicobacter Infections - therapy Helicobacter pylori Helicobacter pylori - physiology Humans Intestine Intestines - microbiology Intestines - pathology Male Metaplasia Metaplasia - microbiology Metaplasia - rehabilitation Middle Aged Mucous membrane Pathogens Precancerous Conditions - microbiology Precancerous Conditions - rehabilitation Recovery of Function - physiology Risk Factors Young Adult |
| title | Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication ‐ a prospective study for up to 10 years |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T07%3A34%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reversibility%20of%20atrophic%20gastritis%20and%20intestinal%20metaplasia%20after%20Helicobacter%20pylori%20eradication%20%E2%80%90%20a%20prospective%20study%20for%20up%20to%2010%20years&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Hwang,%20Y.%E2%80%90J.&rft.date=2018-02&rft.volume=47&rft.issue=3&rft.spage=380&rft.epage=390&rft.pages=380-390&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.14424&rft_dat=%3Cproquest_cross%3E1985684040%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1985684040&rft_id=info:pmid/29193217&rfr_iscdi=true |